By Mill Chart
Last update: Jan 16, 2024
Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ALKERMES PLC (NASDAQ:ALKS) is suited for growth investing. Investors should of course do their own research, but we spotted ALKERMES PLC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.
ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.
Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 602 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALKS get a neutral evaluation. Nothing too spectacular is happening here. ALKS is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make ALKS a good candidate for value and growth investing.
Check the latest full fundamental report of ALKS for a complete fundamental analysis.
More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
ALKERMES PLC
NASDAQ:ALKS (4/23/2024, 10:39:46 AM)
24.56
+0.49 (+2.04%)
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.